On March 28, 2025, Vertex Pharmaceuticals announced that its VX-264 diabetes treatment will not proceed further in development, leading to an expected non-cash impairment charge of about $400 million for 2025. The results of this impairment analysis will be disclosed in their upcoming quarterly report.